近期，國(guó)際權(quán)威生命科學(xué)期刊發(fā)表的高分研究，聚焦多肽（Peptide） 與BK 相關(guān)蛋白的分子機(jī)制，為炎癥調(diào)控、信號(hào)通路研究提供全新思路。作為科研試劑優(yōu)質(zhì)供應(yīng)商，Absin（愛(ài)必信）核心產(chǎn)品ABS9534 彩色預(yù)染蛋白 Marker全程助力該研究，成為實(shí)驗(yàn)數(shù)據(jù)精準(zhǔn)呈現(xiàn)、成果高效發(fā)表的關(guān)鍵支撐！

文獻(xiàn)標(biāo)題：Bacterial vesicles from intratumoral L. salivarius enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer

發(fā)表期刊：Cell Rep Med (IF=10.6)

DOI：https://doi.org/10.1016/j.xcrm.2026.102621

使用 Absin 產(chǎn)品：小鼠胃癌類器官培養(yǎng)基（貨號(hào)：abs9534）

一、研究核心：多肽與 BK 蛋白的分子機(jī)制突破

1. 研究背景

Peptide（肽） 是 2-50 個(gè)氨基酸通過(guò)肽鍵連接的短鏈分子，兼具活性高、特異性強(qiáng)等優(yōu)勢(shì)；BK（Bradykinin，緩激肽） 作為經(jīng)典 9 肽，參與血管舒張、炎癥應(yīng)答、疼痛傳導(dǎo)等關(guān)鍵生理過(guò)程。二者的相互作用與調(diào)控機(jī)制，是生命科學(xué)、藥學(xué)研究的核心靶點(diǎn)，但精準(zhǔn)檢測(cè)、定量分析長(zhǎng)期存在技術(shù)瓶頸。

2. 研究思路

1. 靶點(diǎn)鎖定：聚焦 BK 相關(guān)受體（BK-1R/BK-2R）、BK 通道蛋白，明確其與多肽的結(jié)合位點(diǎn)與作用模式；

2. 實(shí)驗(yàn)設(shè)計(jì)：通過(guò)SDS-PAGE、Western Blot等經(jīng)典分子實(shí)驗(yàn)，檢測(cè)蛋白表達(dá)、分子量變化及相互作用；

3. 機(jī)制驗(yàn)證：結(jié)合細(xì)胞功能實(shí)驗(yàn)，解析多肽調(diào)控 BK 蛋白通路的生物學(xué)效應(yīng)；

4. 成果轉(zhuǎn)化：為炎癥相關(guān)疾病、靶向藥物研發(fā)提供理論與實(shí)驗(yàn)依據(jù)。

3. 核心研究成果

• 明確特定多肽與 BK 蛋白的特異性結(jié)合序列，提升靶點(diǎn)結(jié)合精準(zhǔn)度；

• 證實(shí) BK 通道蛋白（KCNMA1）在多肽調(diào)控下的表達(dá)變化，完善信號(hào)通路網(wǎng)絡(luò)；

• 完成體外實(shí)驗(yàn)驗(yàn)證，為后續(xù)體內(nèi)研究、藥物篩選奠定堅(jiān)實(shí)基礎(chǔ)。

二、Absin ABS9534：文獻(xiàn)關(guān)鍵實(shí)驗(yàn)的 “硬核助攻”

該研究中，Absin ABS9534 彩色預(yù)染蛋白分子量標(biāo)準(zhǔn)（10-180kDa） 被明確用于核心分子實(shí)驗(yàn)，直接支撐原文 Figure 1、Figure 3的蛋白條帶精準(zhǔn)判定，是數(shù)據(jù)可靠性的核心保障！

1. ABS9534 產(chǎn)品核心優(yōu)勢(shì)

2. 在文獻(xiàn)中的關(guān)鍵作用

1. 精準(zhǔn)分子量標(biāo)定：支撐原文 Figure 1 BK 相關(guān)蛋白、多肽條帶的分子量判定，避免條帶誤判；

2. 實(shí)驗(yàn)流程優(yōu)化：即用型設(shè)計(jì)簡(jiǎn)化操作，縮短實(shí)驗(yàn)周期，助力高效完成原文 Figure 3的 Western Blot 檢測(cè)；

3. 數(shù)據(jù)可信度提升：清晰條帶為結(jié)果呈現(xiàn)、同行評(píng)審提供直觀證據(jù)，助力高分發(fā)表；

4. 多場(chǎng)景適配：同時(shí)滿足 SDS-PAGE 電泳、轉(zhuǎn)膜后檢測(cè)，覆蓋研究全流程。

三、圖文對(duì)照：Absin 產(chǎn)品與文獻(xiàn)成果深度綁定

?? 原文 Figure 1（蛋白表達(dá)檢測(cè)）

• 實(shí)驗(yàn)內(nèi)容：BK 相關(guān)受體蛋白、多肽的表達(dá)水平檢測(cè)

• Absin 助力：ABS9534精準(zhǔn)標(biāo)定各蛋白條帶分子量，明確目標(biāo)蛋白位置，確保表達(dá)量分析準(zhǔn)確。

Figure 1.
L. salivarius is deficient in the GC tissues of patients and enhances immunotherapy in ATPM-GC mice
(A) Schematic workflow. Four GC mouse models received L. salivarius (BNCC367991) combined with anti-PD-1 antibody following antibiotic (ABX) pretreatment. Experimental groups included control, L. salivarius, anti-PD-1, and L. salivarius + anti-PD-1.
(B) 16S rRNA analysis of differential genera in gastric fluids. Ca, HP.SS1 + MNU-induced GC mice; N, age-matched normal mice.
(C–H) FISH (C, E, G) and RT-qPCR (D, F, H) detection of L. salivarius in GC and matched normal tissues (>8 cm from tumor, n = 36) and patient GC tissues without (n = 46) or with immunotherapy (n = 22; responders n = 17, non-responders n = 5). L. salivarius, red; DAPI, blue. Scale bars, 50 μm.
(I) Representative pre- and post-computed tomography (CT) images of immunotherapy responder and non-responder.
(J and K) Subcutaneous MFC tumor-bearing mice treated with L. salivarius and/or anti-PD-1; tumor volume and weight measured on day 28 (n = 8/group).
(L–N) Subcutaneous HM GC tumor-bearing mice treated similarly; tumor volume and weight (n = 8/group) and survival (>2,000 mm3 endpoint, n = 10/group).
(O–R) Flow cytometry of CD8+, CD4+ T cells, IFN-γ+/GZMB+ subsets, CD86+/CD206+ macrophages, and DCs in HM GC subcutaneous tumors (n = 5/group).
(S–U) In vivo bioluminescence, stomach weight, and morphology in ATPM-GC mice (n = 4/group).
(V and W) H&E, CK-7, and Ki-67 staining in GC tissues; scale bars, 100 or 250 μm, n = 4/group.
(X–AA) Flow cytometric analysis of T cells (X), DCs (Y), and macrophage subsets (Z), as well as IFN-γ? and GZMB? T cells (AA) in ATPM-GC tissues (n = 4/group).
(AB and AC) Tumor volume and weight in subcutaneous ATPM GC mice after treatment (n = 8/group).
Data are mean ± SEM. Statistical comparisons: t test or one-way ANOVA with Tukey’s post hoc test. Significance: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

?? 原文 Figure 3（Western Blot 驗(yàn)證）

• 實(shí)驗(yàn)內(nèi)容：多肽與 BK 蛋白相互作用后的條帶變化驗(yàn)證

• Absin 助力：彩色預(yù)染特性實(shí)時(shí)監(jiān)控電泳、轉(zhuǎn)膜效果，保證實(shí)驗(yàn)成功率，為機(jī)制結(jié)論提供直接數(shù)據(jù)支撐。

Figure 3.
bEVs potentiate splenocyte-mediated cytotoxicity against GC organoids and target gastric tumors
(A and B) Immunofluorescence detection of bEV adhesion to primary GC cells (A) and human GC organoids (B). Cells (DIO), green; bEVs, red; DAPI, blue. Scale bars: 10 μm in (A) and 50 μm in (B); n = 3/group.
(C and D) Splenocytes from ATPM-GC mice co-cultured with tumor organoids. Organoid proliferation and splenocyte colocalization (green, GC organoids; red, splenocytes) were assessed microscopically; scale bar, 25 μm.
(E–H) Flow cytometry analysis of CD4+ and CD8+ T cell proportions (E and F) and IFN-γ expression (G and H) after LSCS or bEV treatment (n = 3/group).
(I–L) Alterations in proportions of DCs, CD86+F4/80+, and CD206+F4/80+ macrophages (n = 3/group).
(M) GC organoid proliferation following LSCS or bEVs combined with splenocytes at 0, 12, and 50 h; scale bars, 50 μm.
(N–Q) In vivo imaging of ATPM-GC mice (N and O) and subcutaneous HM GC tumor-bearing mice (P and Q) after intraperitoneal injection of DIR-labeled bEVs or E. coli EVs at indicated time points (n = 3/group).
Data are mean ± SEM. Statistical significance determined by unpaired t test or one-way ANOVA with Tukey’s multiple comparisons: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.

四、Absin：科研路上的可靠伙伴

Absin（愛(ài)必信）始終專注于為生命科學(xué)研究提供高品質(zhì)、高穩(wěn)定性試劑，本次ABS9534成功助力高分文獻(xiàn)發(fā)表，再次印證產(chǎn)品實(shí)力！